The overall 5-year survival rate for pancreatic cancer is 13%, based on data from people diagnosed between 2015 and 2021. That makes it one of the most lethal cancers, but the number varies enormously depending on how early it’s caught, the type of tumor, and whether surgery is possible.
Survival Rates by Stage at Diagnosis
Stage matters more for pancreatic cancer than for almost any other cancer type. The gap between early detection and late diagnosis is dramatic:
- Localized (cancer is confined to the pancreas): 44% five-year survival
- Regional (cancer has spread to nearby lymph nodes or tissues): 17%
- Distant (cancer has spread to other organs, most often the liver or lungs): 3%
The problem is that most pancreatic cancers aren’t found early. The pancreas sits deep in the abdomen, and tumors there rarely cause symptoms until they’ve grown large or spread. By the time most people are diagnosed, the cancer has already reached a regional or distant stage.
Stage IV: What the Numbers Look Like
For someone diagnosed with stage IV pancreatic cancer, meaning it has metastasized to distant organs, the median survival time is less than one year. That’s the point at which half of patients have lived longer and half shorter. Some people do survive well beyond that median, particularly those who respond well to treatment, but the 5-year survival rate at this stage is only about 3%.
This is the stage where most diagnoses land, which is the main reason the overall survival number is so low. If pancreatic cancer were routinely caught at the localized stage, the picture would look very different.
How Tumor Type Changes the Outlook
Not all pancreatic cancers behave the same way. About 90% are adenocarcinomas, which start in the cells lining the pancreatic ducts. These are the aggressive tumors that drive the low survival statistics most people see. The 5-year survival rate for pancreatic adenocarcinoma is roughly 10 to 11%.
Pancreatic neuroendocrine tumors (sometimes called PNETs) are far less common but far more survivable. These tumors grow in the hormone-producing cells of the pancreas and tend to be slower-growing. Their 5-year survival rate is approximately 75 to 90%, depending on the population studied. That’s an enormous difference, and it’s worth knowing which type has been diagnosed, because the prognosis and treatment path are fundamentally different.
The Role of Surgery
Surgery is the only treatment that offers a realistic chance of long-term survival for pancreatic adenocarcinoma, but only about 15 to 20% of patients have tumors that are surgically removable at the time of diagnosis. The rest are either too advanced or too entangled with major blood vessels.
The most common surgery is the Whipple procedure, which removes the head of the pancreas along with part of the small intestine, bile duct, and sometimes a portion of the stomach. It’s a major operation. One study found that 22.5% of patients who underwent a Whipple procedure for pancreatic cancer were still alive five years later. That’s a meaningful improvement over the overall statistics, though it reflects a group that was already healthier and had more favorable tumor characteristics to qualify for surgery in the first place.
Surgery is typically followed by chemotherapy to reduce the risk of recurrence. How well someone responds to that follow-up treatment matters significantly for long-term outcomes.
Tracking Treatment Response
A blood marker called CA 19-9 plays an important role in monitoring pancreatic cancer before and after treatment. It’s not useful as a screening tool for the general population, but in someone with a known diagnosis, changes in CA 19-9 levels can signal whether treatment is working.
After surgery, patients whose CA 19-9 levels drop to low levels tend to have better outcomes. Those with levels that remain elevated above 90 U/ml after surgery appear to get less benefit from standard chemotherapy. In one analysis, patients with lower post-surgical CA 19-9 had a median survival of 26 months compared to about 17 months for those with persistently high levels. Doctors use this marker alongside imaging to guide treatment decisions during follow-up.
Are Survival Rates Improving?
Yes, though slowly. A decade ago, the overall 5-year survival rate for pancreatic cancer was in the single digits, hovering around 5 to 7%. The current rate of 13% represents real progress, driven largely by more effective chemotherapy combinations and better surgical techniques at high-volume cancer centers. Localized-stage survival has climbed to nearly 44%, a number that would have been difficult to imagine 15 years ago.
The gains have been incremental rather than dramatic. Pancreatic cancer remains exceptionally difficult to treat because of how it interacts with surrounding tissue, its resistance to many therapies, and the late stage at which it’s typically found. But the trend line is moving in the right direction, and the pace of improvement has accelerated in recent years compared to earlier decades.